Press Release : Roche's Xofluza approved by the -2-

medicines developed by Roche are included in the World Health 
Organization Model Lists of Essential Medicines, among them life-saving 
antibiotics, antimalarials and cancer medicines. Moreover, for the 
twelfth consecutive year, Roche has been recognised as one of the most 
sustainable companies in the Pharmaceuticals Industry by the Dow Jones 
Sustainability Indices (DJSI). 
 
 
 
   The Roche Group, headquartered in Basel, Switzerland, is active in over 
100 countries and in 2019 employed about 98,000 people worldwide. In 
2019, Roche invested CHF 11.7 billion in R&D and posted sales of CHF 
61.5 billion. Genentech, in the United States, is a wholly owned member 
of the Roche Group. Roche is the majority shareholder in Chugai 
Pharmaceutical, Japan. For more information, please visit 
https://www.globenewswire.com/Tracker?data=f80K8YBDFMyK0FHs3YP9myOmEafICaAMKaa1Zu9tl58ZLFptNqlVTYiMS-bdcMW3jKnVzmwwWFAUjaaCZQ2SYg== 
www.roche.com. 
 
 
 
   All trademarks used or mentioned in this release are protected by law. 
 
 
 
   References 
 
   [1] Hayden F, et al. Baloxavir Marboxil for Uncomplicated Influenza in 
Adults and Adolescents. N Engl J Med 2018; 379:913-923. 
 
   [2] Ison M, et al. Early treatment with baloxavir marboxil in high-risk 
adolescent and adult outpatients with uncomplicated influenza 
(CAPSTONE-2): a randomised, placebo-controlled, phase 3 trial. Lancet 
Infect Dis. 2020;20(10):1204-1214. 
 
   [3] Ikematsu H, et al. Baloxavir Marboxil for Prophylaxis against 
Influenza in Household Contacts. N Engl J Med. 2020; 383.309-320. 
 
   [4] EMA. Tamiflu. [Internet; cited 2020 November]. Available from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSzFHK5th4hOixWpiYHeiFgP7U5R0a34jRlz7hyyztmwP2GhBYGzsftVFbp60VZLXLMUvvtF2oIvXESkOCfocX123UPzftLZ55oSuI07UgkHgQtLtVRvg1XvY0c6VaSiRxVYP8schnyrjtvqf5ONROpDMUdJFV7OxflIxWtLL7DW 
https://www.ema.europa.eu/en/medicines/human/EPAR/tamiflu 
 
   [5] Centers for Disease Control and Prevention. Disease burden of 
influenza. [Internet; cited 2020 November]. Available from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSaIOH4mijXNVTdXaopdrk7cszqjaQ-d0jBUNtpvXKYLVynD32U7_i1ZQ_9auZrolsyo717uafKLl82u-XTWGRZTXUFjj4pJqy26KuJdfYUlgTSFsce4F00wZ1fL45y7F8hJs0zcDbcnf6aYnM00j6c= 
https://www.cdc.gov/flu/about/burden/index.html 
 
   [6] World Health Organization. Public Health Research Agenda for 
Influenza. [Internet; cited 2020 November]. Available from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgy0JL2AKVad3muCIjDaqCkrnYyNW-5cUCP_agfqO-e_hw4WYnCNJ85SgTyFGonzM4aaYmt-trjrct5qwUjPYjOSUf86380aHAitriKBvgDwh0LbEb5weN_0ayvHi4Fev9lbwVvTAPNM0OKfa6V6Kf5D0ZOgPd2p0cAq_BV_YV2JtHH-lNd3t-dMDvVPuYQ1H1YMospQ-H_fWFgNt7Z2KTiGHePPINxSL7kMrOFmvcNG_znn-UI1ofKE7bHuORAee33drpL3BkrMzAIfnUadcTwdG0UPQ0kOS8wegHUyN_2osw== 
https://www.who.int/influenza/resources/research/2010_04_29_global_influenza_research_agenda_version_01_en.pdf 
 
 
   [7] World Health Organization. Global Influenza Strategy 2019-2030. 
[Internet; cited 2020 November]. Available from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgzZVGWW2BRP_f6l3qhMnnRDqPwGnZM9HCaH48JVNUCqzcAnSMnDrse_HehmwWmY2C0p8Rr1LG1gfyzq13efr-DDgBGsz9KaqRRN7irbm0x9PJA6O5zGjlTAMWYBmWJ7xu1AGyynqNuOOWXcVIfkdrQw2UbZZRmKXh2uOLh54Xx8TGPk1kYJzav3A9f2wIDZBGaS7Ag2c6Lh_Y4wILYBipEk_F_wNI-iqyyC4Xtcncs43g== 
https://www.who.int/influenza/Global_Influenza_Strategy_2019_2030_Summary_English.pdf?ua=1 
 
 
   [8] World Health Organization. Influenza (seasonal). [Internet; cited 
2020 November]. Available from: 
 
   https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taVtWDTn5b5LFMHt59DyoYgyd7K2qQx8dutnM1ngD3YJexjaVFNEnl5QumJLrYMP1P_7jaIVb3XHPD36oHFurAXZVIXZAiZPcKIuPwVbenxynuwTl2V3S6cxfpp_iQgvJVdzCC5JJaw8EFbage6rea8QC-GynSU4KglNHz6WX6gPx2M4Z5zl1Z61ntnEeTPRJLsy0G5ZuIVrAmrHhUiZ_SJ0= 
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal) 
 
   [9] Choi WS, et al. Severe influenza treatment guideline. Korean J 
Intern Med. 2014; 29.1.132-147. 
 
   [10] World Health Organization. Influenza -- estimating the burden of 
disease. [Internet; cited 2020 November]. Available from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taUS5zu5tPmBPFDOmb2HunljH71lX5CCe8ACGLPlpvzGit62w2bDwt2b0HcO8iCjJv2plIz9oXkJbOIfupylRQYhTOYNW9d9uiMC842jij5R2wrugiPAf1zc6vwHqSJdR85heuo-ChMkuiGFkKH5SrLs451zd3HDs915cbdby_OF6n69FcY5s8fp2SGpxAlu-XxVV2pe5czzHDOPNW7W4esPY1-nXhaSweaETBrNbAHvvVV-qMK9gJ-AxBdlDqJCRLzJuapLbsDyywLma63o-KkikZXbBdkZXN7pPoPvU6kxe-fw4ycTdRDS5Sk3_FKOtjg== 
https://www.euro.who.int/en/health-topics/communicable-diseases/influenza/seasonal-influenza/burden-of-influenza 
 
 
   [11] Trigueiro-Loruro JM, et al. Virol. 2019;535:297-307. 
 
   [12] Mifsud, EJ, et al. Antiviral Res. 2019;169:104545. 
 
   [13] Hayden FG, & Pavia AT. Antiviral management of seasonal and 
pandemic influenza. J Infect Dis. 2006;194:S119--126. 
 
   [14] Uyeki TM, et al. Clinical practice guidelines by the Infectious 
Diseases Society of America: 2018 update on diagnosis, treatment, 
chemoprophylaxis, and institutional outbreak management of seasonal 
influenza. Clin Infect Dis. 2019; doi:10.1093/cid/ciy866. 
 
   [15] Wallick C, et al. Presented at: IDWeek; 2018 October 3-7; San 
Francisco. Abstract #2347. 
 
   [16] Centers for Disease Control and Prevention. What You Should Know 
About Flu Antiviral Drugs. [Internet; cited 2020 November]. Available 
from: 
https://www.globenewswire.com/Tracker?data=8bMQ-w4R4B0FCrxi1j0taSaIOH4mijXNVTdXaopdrk540AwjGxj0OVASa341SESmXFp9BSfe7LLUbI4P97Y9yZl2a6Tad97RvPnHPgBLrxE0-ie_BuVbTsw_53E-h-HQXHONOQPBT1RDLl_nhQnOX0Laj3X2UYWvcV4RdF1_7ZQ= 
https://www.cdc.gov/flu/treatment/whatyoushould.htm 
 
   [17] Noshi T, et al. In vitro Characterization of Baloxavir Acid, a 
First-in-Class Cap-dependent Endonuclease Inhibitor of the Influenza 
Virus Polymerase PA Subunit. Antiviral Research. 2018; 160:109-117. 
 
   [18] Taniguchi K, et al. Inhibition of avian-origin influenza A (H7N9) 
virus by the novel cap-dependent endonuclease inhibitor baloxavir 
marboxil. Scientific Reports. 2019; 9:3466. 
 
   [19] Noshi T, et al. S-033447/S-033188, a Novel Small Molecule Inhibitor 
of Cap-dependent Endonuclease of Influenza A and B Virus. 
 
   [20] In Vitro Antiviral Activity against Laboratory Strains of Influenza 
A and B Virus in Madin-Darby Canine Kidney Cells. Poster presentation at 
OPTIONS IX, August 2016. 
 
 
 
 
 
   Roche Group Media Relations 
 
   Phone: [phone] / e-mail: 
https://www.globenewswire.com/Tracker?data=FYgrBMAt4uHXizJ52cr8TDfPcv9-nlIsVdP_6516wPHFR0k20pLqrkPJugerLB229eyxFA9uRW3uwqWcMHTmWlUqzWhj6Df1CE57vj1cpN1Ps_ZPf955HXIKY_rtC2zO 
[e-mail] 
 
 
 
 
 
 
 
 
Dr. Nicolas Dunant          Patrick Barth 
 Phone: [phone]     Phone: [phone] 
Dr. Daniel Grotzky          Karsten Kleine 
 Phone: [phone]     Phone: [phone] 
Nina Mählitz           Nathalie Meetz 
 Phone: [phone]     Phone: [phone] 
Dr. Barbara von Schnurbein 
 Phone: [phone] 
 
 
 
 
 
 
Roche Investor Relations 
Dr. Karl Mahler                               Jon Kaspar Bayard 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]          e-mail: mailto:[e-mail] 
 [e-mail]                         [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Sabine Borngräber                    Dr. Bruno Eschli 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]   e-mail: mailto:[e-mail] 
 [e-mail]                  [e-mail] 
--------------------------------------------  ------------------------------------------- 
Dr. Birgit Masjost                            Dr. Gerard Tobin 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]       e-mail: mailto:[e-mail] 
 [e-mail]                      [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
Investor Relations North America 
Loren Kalm                                    Dr. Lisa Tuomi 
 Phone: [phone]                        Phone: [phone] 
 e-mail: mailto:[e-mail]            e-mail: mailto:[e-mail] 
 [e-mail]                           [e-mail] 
--------------------------------------------  ------------------------------------------- 
 
 
 
   Attachment 
 
 
   -- 11012021_Xofluza_EC approval_en 
      https://ml-eu.globenewswire.com/Resource/Download/20d2adda-ac6d-4578-8918-10c0e54ba247

(END) Dow Jones Newswires

January 11, 2021 01:00 ET (06:00 GMT)